Stock itci.

ITCI The Nasdaq Global Select Market ... Common stock, $ 0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, ...

Stock itci. Things To Know About Stock itci.

Find the latest Institutional Holdings data for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com.Intra-Cellular Therapies Inc (ITCI) USD0.0001 ... Market cap. ... Data delayed by at least 15 minutes. * To buy US shares you must first complete and return a US ...ITCI, -14836.0 shares, $-823694.72, 2023-08-31, N-PORT. No recent transactions ... Stock Lookup. Enter stock name: use * for wildcard.Covering ITCI for Jefferies, analyst Andrew Tsai writes: “In 2022, we think ITCI stock could break all-time highs despite a challenging tape, as Caplyta scripts are accelerating earlier (and ...

May 10, 2022 · Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit. However, analysts -- and likely investors -- had been bracing for worse ... 04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ...Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023.

Aquí nos gustaría mostrarte una descripción, pero el sitio web que estás mirando no lo permite.To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios. Stocks with a Value Score from 81-100 are considered deep value, those with a score between 61-80 are value and so on. Intra-Cellular Therapies Inc has a Value Score of 5, which is Ultra Expensive.

Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ITCI stock stock is $78.5, which predicts an increase of 34.05%. The lowest target is $62 and the highest is $101. On average, analysts rate ITCI stock stock as a strong buy.Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ...ITCI Message Board Palm Beach, FL – March 11, 2021 – All parts of the fitness and wellness markets had a shakeup in 2020 due to the pandemic—how we work out, what we eat, the products we put on our faces, the way we rest—and the reverberations of those changes will be felt into 2021 and beyond.ITCI is a biopharmaceutical company that develops novel drugs for treating neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. On August 22, 2022, The Goldman Sachs Group Inc. ( GS ) downgraded ITCI from a “buy” rating to a “neutral” rating.

0001193125-21-155623.txt : 20210510 0001193125-21-155623.hdr.sgml : 20210510 20210510073115 ACCESSION NUMBER: 0001193125-21-155623 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT

Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit. However, analysts -- and likely investors -- had been bracing for worse ...April 27, 2023 at 10:03 AM · 5 min read. Wall Street expects a year-over-year increase in earnings on higher revenues when Intra-Cellular Therapies (ITCI) reports results for the quarter ended ...Real time Intra-Cellular Therapies (ITCI) stock price quote, stock graph, news & analysis. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Market Cap. MediciNova Inc. -2.63%. $90.74M. ITCI | Complete Intra-Cellular Therapies Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial...Intra-Cellular Therapies Market Cap: 5.69B, Enterprise value: 5.39B, P/E: -21.66, PEG ratio: -0.97, EPS: -1.54, Revenue: 418.10M, EBITDA: -172.56M, ...

Based on analysts offering 12 month price targets for ITCI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .2 thg 11, 2023 ... ... stock report on ITCI at https://www.zacks.com/ap/ITCI. Advertisement. Sign up for the Daily Brief. Our free, fast, and fun briefing on the ...Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report. ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report. Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report.February 22, 2023 at 10:00 AM · 5 min read. The market expects Intra-Cellular Therapies (ITCI) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Zacks - Wed Mar 29, 11:27AM CDT . Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

On December 9, 2022, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stock closed at $51.77 per share. One-month return of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was 1.09%, and its shares ...Biotech Alert: Searches spiking for these stocks today May 5, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Phibro Animal Health (PAHC) and ...

Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ...Read why ITCI stock is a Hold. Intra-Cellular Therapeutics develops small molecule drugs targeting the CNS for neuropsychiatric and neurological disorders. Read why ITCI stock is a Hold.Stock Price Forecast. The 13 analysts offering 12-month price forecasts for Intra-Cellular Therapies Inc have a median target of 76.00, with a high estimate of 101.00 and a low estimate of 58.00 ...SVB Securities analyst Marc Goodman reiterated a Buy rating on Intra-Cellular Therapies (ITCI – Research Report) yesterday and set a price target of $70.00.The company’s shares opened today at ...According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Nov 24, 2023 · Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Dec 1, 2023 · The average price recommended by analysts for Intra-Cellular Therapies Inc (ITCI) is $77.54, which is $16.26 above the current market price. The public float for ITCI is 93.65M and currently, short sellers hold a 3.65% of that float. On December 01, 2023, ITCI’s average trading volume was 845.52K shares. Top 5 EV Tech Stocks to Buy for 2023. What is Intra-Cellular Therapies Inc (ITCI)'s stock price today? The current price of ITCI is $59.42. The 52 week high of ITCI is $67.05 and 52 week low is $42.01. When is next earnings date of Intra-Cellular Therapies Inc (ITCI)?If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.

NasdaqGS:ITCI Insider Trading Volume December 3rd 2023. For those who like to find winning investments this free list of growing companies with recent insider …

ITCI 4.98%. 58. See ITCI Report. Overall market sentiment has been high on Intra-Cellular Therapies Inc ( ITCI) stock lately. ITCI receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Intra-Cellular Therapies Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ITCI!Ticker Symbol: ITCI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001567514: CUSIP Number: 46116X101: ISIN Number: US46116X1019itci The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing ...Nov 17, 2023 · Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ITCI stock stock is $78.5, which predicts an increase of 34.05%. The lowest target is $62 and the highest is $101. On average, analysts rate ITCI stock stock as a strong buy.Earnings announcement* for ITCI: Nov 08, 2022. Intra-Cellular Therapies Inc. is estimated to report earnings on 11/08/2022. The upcoming earnings date is derived from an algorithm based on a ...Find the latest on option chains for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com ... Financial analysts and individual investors can rely on the chain to gauge the stock's ...May 25, 2023 · sdominick. Introduction. Intra-Cellular Therapies (NASDAQ:ITCI), a pioneering biotech firm, is dedicated to the creation and market introduction of novel small molecule therapies, which are ...

8 thg 7, 2022 ... symbol “ITCI.” 7. Defendant Sharon Mates, Ph.D ... annual stock option grant to purchase 20,000 shares of the Company's common stock, and initial.1.05%. ¥6.6T. VST Industries Ltd. 0.49%. ₹52.52B. ITC | Complete ITC Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.In addition, Intra-Cellular has granted the underwriters a 30-day option to purchase up to an additional 921,300 shares of common stock. In connection with the offering, shares of Intra-Cellular common stock will commence trading on the NASDAQ Global Select Market tomorrow morning under the ticker "ITCI."Nov 24, 2023 · Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Instagram:https://instagram. coin where to buygoogle ipo pricepbj etfpru stock dividend Chg %. Market Cap. MediciNova Inc. -2.63%. $90.74M. ITCI | Complete Intra-Cellular Therapies Inc. stock news by MarketWatch. View real-time stock prices and stock … gm digital retail platformbeat banks March 31, 2023 at 11:30 AM · 4 min read. It has been about a month since the last earnings report for Intra-Cellular Therapies (ITCI). Shares have added about 20.5% in that time frame ... nio phone Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 5.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?The average twelve-month price prediction for Intra-Cellular Therapies is $78.67 with a high price target of $101.00 and a low price target of $62.00. Learn more on ITCI's analyst rating history. Do Wall Street analysts like Intra-Cellular Therapies more than its competitors?Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.